SecBot SecBot
424B5 ·Filed Nov 9, 2026

JAGX

Jaguar Health, Inc.
BEARISH
Impact 6/10
Horizonweeks Processed12d 22h ago SEC0001193125-26-452741
Notable filing: 424B5
Actionable Insight ▼ Bearish

Monitor quarterly ATM sales disclosures for actual drawdown amounts. The extreme size relative to market cap means any meaningful sales will be highly dilutive. Watch for potential Nasdaq continued listing compliance issues given the massive share count increase.

DirectionBearish
Confidencehigh
Horizonweeks

Drugs in focus

JAGX drug pipeline →

Gelclair

● Neutral Named in this 424B5
Impact
Phase
Approved
Time to market
Already FDA-approved and commercially launched in the U.S. as of October 2024.
Next catalyst
None dated

What to watchGelclair is already approved and launched, so the main thing to watch is whether Jaguar's commercial efforts gain traction in the oral mucositis market. The company has shifted strategic focus to rare-disease crofelemer programs (MVID NDA filing targeted mid-2027) and out-licensed its core Mytesi/Canalevia products to Future Pak in January 2026. Gelclair appears to be a smaller part of the portfolio now. The near-term binary catalyst for JAGX is the December 21, 2026 PDUFA for Canalevia (veterinary CID), not Gelclair.

How the stock moved after the report

BEARISH VIEWSTOCK BELOW ENTRY AT T+5
Entry
$0.4361
T+0 close · Nov 9, 2026 · via day close
Latest settled
−11.40%
T+5 · $0.3864 · next T+20 in 16d
Vs SPY
−9.70%
α at T+5
Latest observation
−7.51%
T+9 · FF3 residual α
  1. T+0 · Nov 9 $0.4361entry
  2. T+1 · 12d ago +0.14%α +0.51% · $0.4367
  3. T+5 · 6d ago −11.40%α −9.70% · $0.3864
  4. T+9 · todayOpen
  5. T+20 · in 16d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Jaguar Health filed a 424B5 prospectus supplement establishing a new $75 million at-the-market (ATM) equity offering program through Ladenburg Thalmann as sole sales agent. The ATM replaces prior programs that had already sold $71.8M and $32.1M under earlier shelves. At a $5M market cap, the $75M program cap represents 15x the company's current market value, signaling extreme potential dilution. Proceeds are for working capital and general corporate purposes, with 10% of net proceeds required to redeem Series P Preferred Stock.

Key Financial Metrics

Offering Size
$75.0M
Underwriters
Ladenburg Thalmann & Co. Inc.

Key Facts

  • New ATM program allows sales of up to $75 million of common stock through Ladenburg Thalmann
  • Company market cap is approximately $5 million, making the program cap 15x current market value
  • 13,345,986 shares outstanding as of November 4, 2026; full drawdown would add ~150M shares (11x dilution)
  • Ladenburg receives 3% commission on gross proceeds
  • 10% of net proceeds must be used to redeem Series P Preferred Stock
  • Company has a history of frequent dilutive offerings (24 registration filings in 24 months)
  • Prior ATM programs sold $71.8M and $32.1M under earlier registration statements

Financial Impact

$75 million ATM program cap versus $5 million market cap; potential dilution of approximately 11x current shares outstanding if fully drawn

dilutionmarket capshare count

Risk Factors

  • Extreme dilution risk: $75M program cap is 15x current $5M market cap
  • Full drawdown would increase share count from ~13.3M to ~163.7M shares (11x dilution)
  • Company has a pattern of repeated equity raises and debt-to-equity exchanges with investors like Streeterville Capital
  • Pre-revenue biotech with going-concern audit opinion; ongoing capital needs likely to persist
  • No minimum offering amount; actual sales depend on market conditions

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (7 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
424B5 Filing (Primary)0001193125-26-452741
Document: 0001193125-26-452741-index-headers.html0001193125-26-452741
Document: 0001193125-26-452741-index.html0001193125-26-452741
Document: 0001193125-26-452741.txt0001193125-26-452741

Track record

33 reports on JAGX

Performance horizon

7 of 7 bullish or bearish reports moved the stock their way by T+60. Best: +97.54% at T+1 after the Apr 27, 2026 report. 20 of 22 went positive at some point.

Filters
  1. Nov 20, 20261d ago 8-K Bearish 5/10 Entry $0.2877 Now $0.2270 +21.10% settles Feb 19
  2. Nov 16, 20265d ago 8-K Bearish 6/10 Entry $0.3864 Now $0.2270 +41.25% settles Feb 12
  3. Nov 9, 202612d ago 424B5 Bearish 6/10 Viewing Entry $0.4361 Now $0.2270 +47.95% settles Feb 5
  4. Nov 6, 202615d ago 8-K Bearish 6/10 Entry $0.4361 Now $0.2270 +47.95% settles Feb 5
  5. Nov 6, 202616d ago EFFECT Bearish 5/10 Entry $0.4043 Now $0.2270 +43.85% settles Feb 4
  6. Nov 3, 202618d ago S-3/A Bearish 5/10 Entry $0.5575 Now $0.2270 +59.28% settles Feb 1
  7. Nov 3, 202618d ago 8-K Neutral 2/10 Entry $0.5575 Now $0.2270 −59.28% settles Feb 1
  8. Oct 29, 202623d ago DEFA14A Bearish 6/10 Entry $2.04 Now $0.2270 +88.87% settles Jan 27
  9. Oct 28, 202624d ago 8-K Neutral 2/10 Entry $2.04 Now $0.2270 −88.87% settles Jan 27
  10. Oct 22, 20264w ago S-3 Bearish 5/10 Entry $2.04 Now $0.2270 +88.87% settles Jan 21
Showing 10 of 33

US Market Status

Market Closed · Opens Mon (26h 36m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 9, 2026